06978 永泰生物－Ｂ
按盤價 
2.780 +0.090 (+3.346%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 資產回報率 (%) | -39.553% | -26.506% | -38.803% | -32.179% | -30.696% |
| 股東資金回報率 (%) | N/A | -233.174% | -98.180% | -47.811% | -36.334% |
| 資本運用回報率 (%) | -205.904% | -139.657% | -105.952% | -47.411% | -38.604% |
邊際利潤分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | N/A | N/A | N/A | N/A | N/A |
| 未計利息、稅項、折舊及攤銷前利潤率 (%) | N/A | N/A | N/A | N/A | N/A |
| 稅前邊際利潤率 (%) | N/A | N/A | N/A | N/A | N/A |
| 純利率 (%) | N/A | N/A | N/A | N/A | N/A |
變現能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流動比率 (X) | 0.350 X | 0.203 X | 0.403 X | 0.567 X | 2.289 X |
| 速動比率 (X) | 0.350 X | 0.203 X | 0.403 X | 0.567 X | 2.289 X |
財務槓桿分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 總負債 / 總資產比率 (%) | 102.854% | 102.917% | 79.807% | 42.421% | 25.008% |
| 總債項 / 總資產比率 (%) | 17.191% | 68.179% | 54.021% | 17.034% | 10.117% |
| 淨債項 / 總資產比率 (%) | 8.159% | 59.854% | 47.858% | 10.388% | -22.072% |
| 總債項 / 股東資金比率 (%) | N/A | N/A | 263.324% | 29.464% | 13.506% |
| 長期債項 / 股東資金比率 (%) | N/A | N/A | 60.856% | 24.339% | 11.048% |
| 淨債項 / 股東資金比率 (%) | N/A | N/A | 233.280% | 17.968% | -29.466% |
| 淨現金 / (債項) ($) | (4.92千萬) | (3.38億) | (4.05億) | (9.14千萬) | 2.42億 |
| 每股淨現金 / (債項) ($) | (0.080) | (0.603) | (0.787) | (0.178) | 0.471 |
| 總債項 / 資本運用比率 (%) | 92.476% | 287.336% | 144.671% | 22.327% | 12.103% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
營運效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存貨周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 應收貿易帳周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 應付貿易帳周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 備註： | 即時報價更新時間為27/03/2026 17:59 |
| 港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
| 股東應佔溢利/(虧損) (千) | RMB -230,785 |
| 增長率 | 23.473% |
| 每股盈利/(虧損) | RMB -0.420 |
| 每股帳面資產淨值 (¥) | RMB -0.023 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
